Table 2 Results of univariate associations and multivariable Cox models of overall and recurrence free survival in NSCLC patients

Age

1.04 (1.03–1.06)

1.01 (0.99–1.03)

1.03 (1.01–1.05)

Gender

0.52 (0.39–0.68)

0.71 (0.50–1.00)

0.31 (0.21–0.46)

0.5 (0.31–0.81)

 Female vs. Male

Race

 African American vs. Caucasian

0.59 (0.31–1.03)

0.55 (0.23–1.09)

 Other vs. Caucasian

1.27 (0.45–2.77)

0.75 (0.12–2.38)

DLCO

0.98 (0.98–0.99)

0.99 (0.98–1.00)

0.98 (0.97–0.99)

FEV₁

0.99 (0.98–0.99)

0.99 (0.98–1.00)

ASA score

1.94 (1.47–2.58)

1.32 (0.93–1.87)

1.35 (1.00- 1.82)

 High vs. Low

SMI

0.98 (0.97–1.00)

0.99 (0.97–1.00)

0.96 (0.95–0.98)

0.97 (0.95–0.99)

BMI²

1.14 (0.85–1.52)

1.21 (0.84–31.0)

Tumor stage

 Stage II vs. Stage I

1.28 (0.94–1.73)

2.18 (1.51–3.13)

1.87 (1.17–2.96)

 Stage III vs. Stage I

1.72 (1.06–2.65)

1.74 (0.89–3.10)

2.2 (1.17–3.98)

Histology

 Squamous Cell Carcinoma vs. Adenocarcinoma

1.57 (1.17–2.09)

0.97 (0.65–1.42)

 Other vs. Adenocarcinoma

1.9 (0.99–3.30)

1.75 (0.78–3.39)

Smoking status

 Current vs. Past

0.81 (0.57–1.11)

0.89 (0.58–1.33)

 Never vs. Past

0.79 (0.48–1.23)

1.11 (0.63–1.85)

Adjuvant Chemotherapy

0.84 (0.61–1.14)

1.61 (1.12–2.29)

 Yes vs. No

Adjuvant Radiation

0.96 (0.52–1.62)

1.55 (0.81–2.69

 Yes vs. No